NN-2101

N/A

Report date: 2024/04/18 11:25:10
First In Class

Base Information

Drug NameNN-2101
Drug Alias NameNN-2101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionStem cell growth factor receptor inhibitors
TargetsStem cell growth factor receptor
Therapy Area/IndicationsDiabetic macular oedemaRetinal Vein OcclusionWet age-related macular degeneration +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovelty Nobility Inc
China Registration ClassN/A

Develop Information

Active CompaniesNovelty Nobility Inc
Inactive CompaniesN/A
Active IndicationsRetinal Diseases
Inactive IndicationsDiabetic macular oedemaRetinal Vein OcclusionWet age-related macular degeneration +[4] 

Other Information

ATC CodeN/A
Related LinksN/A